HIGHLIGHTS
- who: Arnold Bolomsky from the Wilhelminenspital, Montleartstraße, Vienna, Austria have published the research: Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment, in the Journal: (JOURNAL)
- what: The authors investigated the anti-MM activity of PTC-209, a novel small_molecule inhibitor of BMI-1.
- how: The authors investigated PTC-209 a novel small molecule inhibitor of BMI-1 for its activity in MM. Methods BMI-1 expression was analysed in human MM cell lines and primary MM cells by using publically available gene expression . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.